Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this ...

GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate ...

GSK teams with LTZ Therapeutics to co-develop next-gen myeloid-cell engager immunotherapies in oncology leveraging LTZ’s innate-immune platform and GSK’s development engine.

LONDON/MUMBAI (Reuters) - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being ...

UK invites pharma executives to help design a new drug-pricing system following a fresh US–UK agreement that raises NHS costs but protects medicine exports.

It’s been an upbeat week for GSK as it reported a trio of positive updates stemming from vaccines and oncology products. Most notable, perhaps, was the news that the British drugmaker took a step ...

UK pharma major GSK has announced that the National Institute for Health and Care Excellence (NICE) has issued final guidance ...

GlaxoSmithKline (GSK) and Dentsply have entered into an agreement to create a portfolio of co-branded oral care products to be used in the dental office by patients suffering from tooth sensitivity.

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK has announced the purchase of 170,000 of its own ordinary shares as part of its ...

AnaptysBio ( ($ANAB) ) has provided an update. On November 20, 2025, AnaptysBio filed a complaint in Delaware Chancery Court against TESARO, Inc.

BEIJING/LONDON (Reuters) -China has blocked GSK from participating in its bulk-buy drug procurement programme focused on off-patent medicines from Oct. 31 until April 29, 2024, over quality problems ...